New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
16:37 EDTSHPG, ANIPANI Pharmaceuticals acquires U.S. rights for Vancocin from Shire
ANI Pharmaceuticals (ANIP) announced that it has acquired the U.S. rights for Vancocin 125 mg and 250 mg capsules from Shire (SHPG). In addition, ANI acquired from Shire approved ANDAs for the currently non-marketed products vancomycin hydrochloride injectable 500 mg, 1 gm and 10 gm and vancomycin hydrochloride oral solution 250 mg and 500 mg. ANI paid $11M in cash for the rights to Vancocin together with existing inventories on hand. Following a transition period, ANI intends to launch Vancocin capsules under its own label during the fourth quarter. The transaction is immediately accretive and sales of Vancocin capsules are expected to generate approximately $5.4M in revenues and $4M in non-GAAP EBITDA annually.
News For ANIP;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
07:04 EDTSHPGShire re-approaching Baxalta is feasible, says Leerink
Subscribe for More Information
November 24, 2015
15:28 EDTSHPGShire working on new Baxalta takeover bid, Reuters reports
Subscribe for More Information
15:16 EDTSHPGShire readying new takeover offer for Baxalta, Reuters says
New bid could be structured as both cash and shares, Reuters says, citing a source.
November 17, 2015
10:00 EDTSHPGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: CF Industries (CF) upgraded to Positive at Susquehanna... ExlService (EXLS) upgraded to Buy from Neutral at BofA/Merrill... Fitbit (FIT) upgraded to Buy at BofA/Merrill... Forward Air (FWRD) upgraded to Outperform at Baird... HD Supply (HDS) upgraded to Positive from Neutral at Susquehanna... Hannover Re (HVRRY) upgraded to Overweight from Underweight at JPMorgan... Moody's (MCO) upgraded to Buy from Neutral at UBS... PRA Group (PRAA) upgraded to Strong Buy from Market Perform at Raymond James... Plum Creek Timber (PCL) upgraded to Outperform from Sector Perform at RBC Capital... Shire (SHPG) upgraded to Outperform from Market Perform at Leerink... Yandex (YNDX) upgraded to Overweight from Equal Weight at Morgan Stanley... Zayo Group (ZAYO) upgraded to Buy from Neutral at MoffettNathanson.
November 16, 2015
16:53 EDTSHPGPaulson reduced stake in Valeant
Paulson & Co. gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Perrigo (PRGO), CIT Group (CIT), Precision Castparts (PCP), Cameron (CAM), and Altera (ALTR). INCREASED STAKES: Teva (TEVA), Post Holdings (POST), Starwood Hotels (HOT), LivaNova (LIVN), and Synergy Pharmaceuticals (SGYP). DECREASED STAKES: Valeant (VRX), Shire (SHPG), Whiting Petroleum (WLL), Computer Sciences (CSC), and Oasis Petroleum (OAS). LIQUIDATED STAKES: Houghton Mifflin Harcourt (HMHC), Broadcom (BRCM), and Sprint (S).
16:18 EDTSHPGShire upgraded to Outperform, price target raised to $239 at Leerink
Subscribe for More Information
16:02 EDTSHPGShire upgraded to Outperform from Market Perform at Leerink
09:59 EDTSHPGOmega bought Valeant in Q3, sold some SuneEdison
Leon Cooperman's Omega Advisors gave a quarterly update on its stakes in a filing this morning, disclosing its positions as of September 30. NEW STAKES: Pfizer (PFE), Valeant (VRX) Walgreens Boots Alliance (WBA), TerraForm Global (GLBL), Cigna (CI). INCREASED STAKES: Google Class A (GOOGL), Facebook (FB), Delta Air Lines (DAL). DECREASED STAKES: SunEdison (SUNE), Shire (SHPG), Citi (C), KAR Auction (KAR), LyondellBasell (LYB). LIQUIDATED STAKES: McKesson (MCK), 21st Century Fox (FOXA), General Motors (GM), QEP Resources (QEP), eBay (EBAY).
06:01 EDTSHPGSynergy Pharmaceuticals appoints Gary Sender as CFO
Subscribe for More Information
November 13, 2015
10:02 EDTANIPANI Pharmaceuticals initiated with a Buy at Standpoint Research
Subscribe for More Information
November 12, 2015
08:02 EDTSHPGSynergy Pharmaceuticals still a saleable asset, says Canaccord
Canaccord still views Synergy Pharmaceuticals (SGYP) as a saleable asset, with Valeant (VRX) or Shire (SHPG) seen as the most obvious buyers. The firm also sees the cost of the launch of plecanatide as lower than expected and sees no need for the company to raise capital until at least the end of 2016. Canaccord reiterated its Buy rating and $19 price target on Synergy Pharmaceuticals shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use